Ishani Landry
About
Ishani Landry is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Molecular Biology.
According to data from OpenAlex, Ishani Landry has authored 26 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cognitive Neuroscience, 14 papers in Experimental and Cognitive Psychology and 9 papers in Molecular Biology. Recurrent topics in Ishani Landry's work include Sleep and Wakefulness Research (15 papers), Sleep and related disorders (14 papers) and Circadian rhythm and melatonin (6 papers). Ishani Landry is often cited by papers focused on Sleep and Wakefulness Research (15 papers), Sleep and related disorders (14 papers) and Circadian rhythm and melatonin (6 papers). Ishani Landry collaborates with scholars based in United States, United Kingdom and Japan. Ishani Landry's co-authors include Margaret Moline, Jagadeesh Aluri, Nancy Hall, Bojan Lalovic, Larisa Reyderman, Gleb Filippov, Kenya Nakai, Oneeb Majid, Beatrice Setnik and Jim Ferry and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Analytica Chimica Acta and SLEEP.
In The Last Decade
Ishani Landry
25 papers receiving 313 citations
Peers
Ishani Landry
J Decourt France
S. Aubrey Stoch United States
Pekka Kaipainen Finland
Danika C.A. Lyons Canada
Adam Weidenhammer United States
Brian Martens United States
Jennifer N. Miller United States
Justin Scott United States
Pamela Wedel United States
Hailong Cheng United States
Citations per year, relative to Ishani Landry Ishani Landry (= 1×)
peers
J Decourt
Countries citing papers authored by Ishani Landry
Since
Specialization
Citations
This map shows the geographic impact of Ishani Landry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ishani Landry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ishani Landry more than expected).
Fields of papers citing papers by Ishani Landry
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ishani Landry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ishani Landry. The network helps show where Ishani Landry may publish in the future.
Co-authorship network of co-authors of Ishani Landry
This figure shows the co-authorship network connecting the top 25 collaborators of Ishani Landry. A scholar is included among the top collaborators of Ishani Landry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ishani Landry. Ishani Landry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yee, Brendon J., Julia L. Chapman, Ronald R. Grunstein, et al.. (2023). O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia. SLEEP Advances. 4(Supplement_1). A5–A6.
2.
Moline, Margaret, Shoji Asakura, Ishani Landry, et al.. (2023). The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology. 240(4). 699–711.
3.
Landry, Ishani, Nancy Hall, Jagadeesh Aluri, et al.. (2022). Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. Journal of Psychopharmacology. 36(6). 745–755.
4.
Landry, Ishani, et al.. (2022). E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies. Alzheimer Disease & Associated Disorders. 36(3). 208–214.
5.
Lalovic, Bojan, Ishani Landry, Margaret Moline, Larisa Reyderman, & Ziad Hussein. (2022). Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia. The Journal of Clinical Pharmacology. 63(4). 498–511.
6.
Hayato, Seiichi, Osamu Takenaka, Ishani Landry, et al.. (2022). Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 11(12). 1578–1591.
7.
Rawal, Sumit, Ishani Landry, Jagadeesh Aluri, et al.. (2022). Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects. Alzheimer s & Dementia. 18(S10).
8.
Landry, Ishani, Jagadeesh Aluri, Edgar Schuck, et al.. (2022). Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027. Alzheimer Disease & Associated Disorders. 36(3). 200–207.
9.
Landry, Ishani, Nancy Hall, Jagadeesh Aluri, et al.. (2022). Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. Journal of Clinical Psychopharmacology. 42(4). 365–373.
10.
Landry, Ishani, Jagadeesh Aluri, Nancy Hall, et al.. (2021). Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females. Clinical Pharmacology in Drug Development. 10(9). 1089–1098.
11.
Landry, Ishani, Jagadeesh Aluri, Nancy Hall, et al.. (2021). Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacology Research & Perspectives. 9(2). e00734–e00734.
12.
Landry, Ishani, Jagadeesh Aluri, Kenya Nakai, et al.. (2021). Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant. Clinical Pharmacology in Drug Development. 10(6). 681–690.
13.
Landry, Ishani, Jagadeesh Aluri, Nancy Hall, et al.. (2020). Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant. Pharmacology Research & Perspectives. 8(6). e00678–e00678.
14.
Lalovic, Bojan, Oneeb Majid, Jagadeesh Aluri, et al.. (2020). Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. The Journal of Clinical Pharmacology. 60(12). 1642–1654.
15.
Landry, Ishani, Kenya Nakai, Jim Ferry, et al.. (2020). Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults. Clinical Pharmacology in Drug Development. 10(2). 153–165.
16.
Vermeeren, Annemiek, Stefan Jongen, Patricia Murphy, et al.. (2018). On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. SLEEP. 42(4).
17.
Landry, Ishani, Robert Lai, Peter D. W. Boyd, et al.. (2018). P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM. Alzheimer s & Dementia. 14(7S_Part_5).
18.
Landry, Ishani, Robert Lai, Peter D. W. Boyd, et al.. (2018). O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES. Alzheimer s & Dementia. 14(7S_Part_4).
19.
Zheng, Naiyu, Jianing Zeng, Qin Ji, et al.. (2016). Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection. Analytica Chimica Acta. 934. 170–179.
20.
Zhu, Li, Matthew Hruska, Carey Hwang, et al.. (2015). Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 59(7). 3816–3822.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J Decourt Breakdown of academic impact, for papers by S. Aubrey Stoch Breakdown of academic impact, for papers by Pekka Kaipainen Breakdown of academic impact, for papers by Danika C.A. Lyons Breakdown of academic impact, for papers by Adam Weidenhammer Breakdown of academic impact, for papers by Brian Martens Breakdown of academic impact, for papers by Jennifer N. Miller Breakdown of academic impact, for papers by Justin Scott Breakdown of academic impact, for papers by Pamela Wedel Breakdown of academic impact, for papers by Hailong Cheng